Axel Sauerbrey
Overview
Explore the profile of Axel Sauerbrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1397
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hommann M, Kaemmerer D, Daffner W, Prasad V, Baum R, Petrovitch A, et al.
J Gastrointest Cancer
. 2011 Jan;
42(4):292-5.
PMID: 21221846
Background: The nested stromal epithelial tumor (NSET) of the liver is a rare tumor entity which is being reported in young girls. Case Report: In our 16-year-old female patient, we...
12.
Glocker E, Kotlarz D, Boztug K, Gertz E, Schaffer A, Noyan F, et al.
N Engl J Med
. 2009 Nov;
361(21):2033-45.
PMID: 19890111
Background: The molecular cause of inflammatory bowel disease is largely unknown. Methods: We performed genetic-linkage analysis and candidate-gene sequencing on samples from two unrelated consanguineous families with children who were...
13.
Laux D, Kratz C, Sauerbrey A
J Pediatr Hematol Oncol
. 2008 Sep;
30(8):602-4.
PMID: 18799937
Germline mutations in PTPN11 gene cause Noonan syndrome and the clinically similar LEOPARD syndrome (LS). LS is a rare congenital developmental disorder characterized by multiple lentigines, cardiac abnormalities, facial dysmorphism,...
14.
Efferth T, Konkimalla V, Wang Y, Sauerbrey A, Meinhardt S, Zintl F, et al.
Clin Cancer Res
. 2008 Apr;
14(8):2405-12.
PMID: 18413831
Purpose: Drug resistance is a major obstacle in cancer chemotherapy. Although the statistical probability of therapeutic success is known for larger patient groups from clinical therapy trials, it is difficult...
15.
Wagner S, Peters O, Fels C, Janssen G, Liebeskind A, Sauerbrey A, et al.
J Neurooncol
. 2007 Jul;
86(2):175-81.
PMID: 17641821
Background: The combination of topoisomerase I and II chemotherapeutic agents has shown promising preclinical synergistic effects in the treatment of high-grade malignant brain tumors such as high-grade gliomas and choroid...
16.
Efferth T, Gillet J, Sauerbrey A, Zintl F, Bertholet V, DE Longueville F, et al.
Mol Cancer Ther
. 2006 Aug;
5(8):1986-94.
PMID: 16928819
A major issue in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) is resistance to chemotherapeutic drugs. Multidrug resistance can be caused by ATP-binding cassette (ABC) transporters. The majority of...
17.
Steinbach D, Gillet J, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, et al.
Clin Cancer Res
. 2006 Jul;
12(14 Pt 1):4357-63.
PMID: 16857811
Background: A major issue in the treatment of acute myeloid leukemia (AML) is resistance to chemotherapeutic drugs. Multidrug resistance can be caused by ATP-binding cassette (ABC) transporters that function as...
18.
Doerfel C, Rump A, Sauerbrey A, Gruhn B, Zintl F, Steinbach D
Pharmacogenet Genomics
. 2006 Jan;
16(2):149-50.
PMID: 16424827
No abstract available.
19.
Steinbach D, Friedrich J, Dawczynski K, Furchtbar S, Gruhn B, Wittig S, et al.
Leuk Lymphoma
. 2005 Aug;
46(9):1357-63.
PMID: 16109615
Drug resistance can be caused by ATP-binding-cassette (ABC)-transporters which function as outward pumps for chemotherapeutic drugs. The aim of the present study was to analyze the association between eight ABC-transporters...
20.
Heller A, Trifonov V, Rubtsov N, Sauerbrey A, Starke H, Loncarevic I, et al.
Oncol Rep
. 2003 Oct;
10(6):1789-92.
PMID: 14534697
We report on the cytogenetic findings from a patient with a de novo TNF-receptor-associated periodic syndrome (TRAPS), who showed first symptoms at the age of four months. Thus, he obtained...